GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Market Cap

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Market Cap : $2.46 Mil (As of May. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aridis Pharmaceuticals's share price for the quarter that ended in Sep. 2023 was $0.1021. Aridis Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 44.57 Mil. Therefore, Aridis Pharmaceuticals's market cap for the quarter that ended in Sep. 2023 was $4.55 Mil.

Aridis Pharmaceuticals's quarterly market cap declined from Mar. 2023 ($11.33 Mil) to Jun. 2023 ($7.93 Mil) and declined from Jun. 2023 ($7.93 Mil) to Sep. 2023 ($4.55 Mil).

Aridis Pharmaceuticals's annual market cap declined from Dec. 2020 ($61.10 Mil) to Dec. 2021 ($41.24 Mil) and declined from Dec. 2021 ($41.24 Mil) to Dec. 2022 ($31.90 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aridis Pharmaceuticals's Enterprise Value for Today is $7.48 Mil.


Aridis Pharmaceuticals Market Cap Historical Data

The historical data trend for Aridis Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Market Cap Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial 89.88 39.69 61.10 41.24 31.90

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.46 31.90 11.33 7.93 4.55

Competitive Comparison of Aridis Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Aridis Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aridis Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Market Cap falls into.



Aridis Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Aridis Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$1.18*27.0335
=$31.90

Aridis Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2023 is calculated as

Market Cap (Q: Sep. 2023 )=Share Price (Q: Sep. 2023 )*Shares Outstanding (EOP) (Q: Sep. 2023 )
=$0.1021*44.574
=$4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aridis Pharmaceuticals  (OTCPK:ARDS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Aridis Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Executives
Fibrosis Foundation Cystic 10 percent owner 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri officer: Chief Medical Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Vu Truong director, 10 percent owner, officer: CEO, CSO, Director 5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer director, 10 percent owner 5941 OPTICAL CT., SAN JOSE CA 95138
John F Hamilton director 1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak officer: Chief Financial Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland officer: Chief Financial Officer C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo director
Shawn Lu director C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin director 5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025